Cepheid Schedules Teleconference and Webcast for First Quarter 2007 Results

SUNNYVALE, Calif., April 30 /PRNewswire-FirstCall/ -- Cepheid (NASDAQ:CPHD) announced today plans to release its financial results for the first quarter ended March 31, 2007 after the market closes on Thursday, May 3, 2007. In conjunction with the release, management will host a conference call that afternoon at 4:30pm (Eastern). The call will be simultaneously broadcast over the Internet.

Interested participants and investors may access the conference call by dialing 800-257-1836 (domestic) or 303-262-2191 (international). There will also be a live webcast of the call on the Investor Relations section of Cepheid's web site at www.cepheid.com under Investors: Events: Webcasts and Presentations. Web participants are encouraged to go to the web site at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.

Cepheid's CEO John L. Bishop and CFO John R. Sluis will be present to discuss Cepheid's financial results, business highlights and outlook. After the live webcast, a replay will remain available in the Investors section of Cepheid's web site for twelve months. A replay of the teleconference will be available at 800-405-2236 (domestic) or 303-590-3000 (international) through May 10, 2007; the conference ID is 11089144.

About Cepheid

Cepheid (NASDAQ:CPHD), based in Sunnyvale, Calif., is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See www.cepheid.com for more information.


    At the Company:

    John L. Bishop                    John R. Sluis
    CEO, Cepheid                      CFO, Cepheid
    408-541-4191                      408-541-4191
    john.bishop@cepheid.com           john.sluis@cepheid.com

    At Financial Relations Board:     At Schwartz Communications:

    Tricia Ross                       Chris Stamm / Tom Bain
    Investor/Analyst Information      781-684-0770
    310-854-8318                      cepheid@schwartz-pr.comtross@frbir.com

Source: Cepheid

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here